Solute Carrier Family 16 Member 1 As a Potential Prognostic Factor for Pancreatic Ductal Adenocarcinoma and Its Influence on Tumor Immunity

Overview

Journal J Gastrointest Oncol

Date 2024 May 17

PMID 38756638

Authors

Meng Wang

Lin Liu

Xinze Li

Wenna Jiang

Jiawei Xiao

Qianhui Hao

Jiayi Wang

Abhinav V Reddy

Alice Talbot

Shinichi Ikuta

Derun Tian

Li Ren

Affiliations

Soon will be listed here.

Abstract

Background: Solute carrier family 16 member 1 () serves as a biomarker in numerous types of cancer. Tumor immune infiltration has drawn increasing attention in cancer progression and treatment. The objective of our study was to explore the association between and the tumor immune microenvironment in pancreatic ductal adenocarcinoma (PDAC).

Methods: Data were obtained from The Cancer Genome Atlas. The xCell web tool was used to calculate the proportion of immune cells according to expression. To further explore the mechanism of , immunity-related genes were screened from differentially expressed genes through weighted gene coexpression network analysis, examined via Gene Ontology and Kyoto Encyclopedia of Genes and Genomes analyses, and filtrated using univariate Cox regression and least absolute shrinkage and selection operator regression model combined correlation analysis (P<0.05). Next, CIBERSORT was used to analyze the correlation between immune cells and five important genes. expression and its clinical role in pancreatic cancer was clarified via immunohistochemical staining experiments. Finally, the effects of on the results of cancer immunity were evaluated by in vitro experiments.

Results: was overexpressed in PDAC tissues and could be an independent prognostic factor. was significantly negatively correlated with overall survival and suppressed the tumor immunity of PDAC. In clinic, expression was significantly positively correlated with tumor progression and poor prognosis. We also found that could suppress the antitumor ability of CD8 T cells.

Conclusions: is a biomarker for the prognosis of PDAC and can influence the immune environment of PDAC. These findings provide new insights into the treatment of PDAC.

References

Park W, Chawla A, OReilly E . Pancreatic Cancer: A Review. JAMA. 2021; 326(9):851-862. PMC: 9363152. DOI: 10.1001/jama.2021.13027. View

Zhao Z, Wu M, Zou C, Tang Q, Lu J, Liu D . Downregulation of MCT1 inhibits tumor growth, metastasis and enhances chemotherapeutic efficacy in osteosarcoma through regulation of the NF-κB pathway. Cancer Lett. 2013; 342(1):150-8. DOI: 10.1016/j.canlet.2013.08.042. View

Liu S, Wang Z, Zhu R, Wang F, Cheng Y, Liu Y . Three Differential Expression Analysis Methods for RNA Sequencing: limma, EdgeR, DESeq2. J Vis Exp. 2021; (175). DOI: 10.3791/62528. View

Chatterjee P, Bhowmik D, Roy S . A systemic analysis of monocarboxylate transporters in ovarian cancer and possible therapeutic interventions. Channels (Austin). 2023; 17(1):2273008. PMC: 10631444. DOI: 10.1080/19336950.2023.2273008. View

Pinheiro C, Penna V, Morais-Santos F, Abrahao-Machado L, Ribeiro G, Curcelli E . Characterization of monocarboxylate transporters (MCTs) expression in soft tissue sarcomas: distinct prognostic impact of MCT1 sub-cellular localization. J Transl Med. 2014; 12:118. PMC: 4036386. DOI: 10.1186/1479-5876-12-118. View

Mizrahi J, Surana R, Valle J, Shroff R . Pancreatic cancer. Lancet. 2020; 395(10242):2008-2020. DOI: 10.1016/S0140-6736(20)30974-0. View

Bremnes R, Busund L, Kilvaer T, Andersen S, Richardsen E, Paulsen E . The Role of Tumor-Infiltrating Lymphocytes in Development, Progression, and Prognosis of Non-Small Cell Lung Cancer. J Thorac Oncol. 2016; 11(6):789-800. DOI: 10.1016/j.jtho.2016.01.015. View

Quanz M, Bender E, Kopitz C, Grunewald S, Schlicker A, Schwede W . Preclinical Efficacy of the Novel Monocarboxylate Transporter 1 Inhibitor BAY-8002 and Associated Markers of Resistance. Mol Cancer Ther. 2018; 17(11):2285-2296. DOI: 10.1158/1535-7163.MCT-17-1253. View

Laface C, Memeo R, Maselli F, Santoro A, Iaia M, Ambrogio F . Immunotherapy and Pancreatic Cancer: A Lost Challenge?. Life (Basel). 2023; 13(7). PMC: 10381818. DOI: 10.3390/life13071482. View

10.

Yoshihara K, Shahmoradgoli M, Martinez E, Vegesna R, Kim H, Torres-Garcia W . Inferring tumour purity and stromal and immune cell admixture from expression data. Nat Commun. 2013; 4:2612. PMC: 3826632. DOI: 10.1038/ncomms3612. View

11.

Heagerty P, Lumley T, Pepe M . Time-dependent ROC curves for censored survival data and a diagnostic marker. Biometrics. 2000; 56(2):337-44. DOI: 10.1111/j.0006-341x.2000.00337.x. View

12.

Seminerio I, Kindt N, Descamps G, Bellier J, Lechien J, Mat Q . High infiltration of CD68+ macrophages is associated with poor prognoses of head and neck squamous cell carcinoma patients and is influenced by human papillomavirus. Oncotarget. 2018; 9(13):11046-11059. PMC: 5834277. DOI: 10.18632/oncotarget.24306. View

13.

Payen V, Hsu M, Radecke K, Wyart E, Vazeille T, Bouzin C . Monocarboxylate Transporter MCT1 Promotes Tumor Metastasis Independently of Its Activity as a Lactate Transporter. Cancer Res. 2017; 77(20):5591-5601. DOI: 10.1158/0008-5472.CAN-17-0764. View

14.

De Saedeleer C, Porporato P, Copetti T, Perez-Escuredo J, Payen V, Brisson L . Glucose deprivation increases monocarboxylate transporter 1 (MCT1) expression and MCT1-dependent tumor cell migration. Oncogene. 2013; 33(31):4060-8. DOI: 10.1038/onc.2013.454. View

15.

Halbrook C, Lyssiotis C, Pasca di Magliano M, Maitra A . Pancreatic cancer: Advances and challenges. Cell. 2023; 186(8):1729-1754. PMC: 10182830. DOI: 10.1016/j.cell.2023.02.014. View

16.

Fischer K, Hoffmann P, Voelkl S, Meidenbauer N, Ammer J, Edinger M . Inhibitory effect of tumor cell-derived lactic acid on human T cells. Blood. 2007; 109(9):3812-9. DOI: 10.1182/blood-2006-07-035972. View

17.

Watson M, Vignali P, Mullett S, Overacre-Delgoffe A, Peralta R, Grebinoski S . Metabolic support of tumour-infiltrating regulatory T cells by lactic acid. Nature. 2021; 591(7851):645-651. PMC: 7990682. DOI: 10.1038/s41586-020-03045-2. View

18.

Tang Z, Li C, Kang B, Gao G, Li C, Zhang Z . GEPIA: a web server for cancer and normal gene expression profiling and interactive analyses. Nucleic Acids Res. 2017; 45(W1):W98-W102. PMC: 5570223. DOI: 10.1093/nar/gkx247. View

19.

Rawla P, Sunkara T, Gaduputi V . Epidemiology of Pancreatic Cancer: Global Trends, Etiology and Risk Factors. World J Oncol. 2019; 10(1):10-27. PMC: 6396775. DOI: 10.14740/wjon1166. View

20.

Henriksen A, Dyhl-Polk A, Chen I, Nielsen D . Checkpoint inhibitors in pancreatic cancer. Cancer Treat Rev. 2019; 78:17-30. DOI: 10.1016/j.ctrv.2019.06.005. View